Hemagglutinin Stalk-binding Antibodies Enhance Effectiveness of Neuraminidase Inhibitors Against Influenza Via Fc-dependent Effector Functions

Overview

Journal Cell Rep Med

Publisher Cell Press

Specialties Biology
General Medicine

Date 2022 Aug 17

PMID 35977467

Authors

Ali Zhang

Hanu Chaudhari

Yonathan Agung

Michael R DAgostino

Jann C Ang

Yona Tugg

Matthew S Miller

Affiliations

Soon will be listed here.

Abstract

The conserved hemagglutinin stalk domain is an attractive target for broadly effective antibody-based therapeutics and next-generation universal influenza vaccines. Protection provided by hemagglutinin stalk-binding antibodies is principally mediated through activation of immune effector cells. Titers of stalk-binding antibodies are highly variable on an individual level and tend to increase with age as a result of increasing exposures to influenza virus. In our study, we show that stalk-binding antibodies cooperate with neuraminidase inhibitors to protect against influenza virus infection in an Fc-dependent manner. These data suggest that the effectiveness of neuraminidase inhibitors is likely influenced by an individual's titers of stalk-binding antibodies and that neuraminidase inhibitors may enhance the effectiveness of future stalk-binding monoclonal antibody-based treatments.

Citing Articles

mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases.

Brandi R, Paganelli A, DAmelio R, Giuliani P, Lista F, Salemi S Vaccines (Basel). 2025; 12(12.

PMID: 39772079 PMC: 11680146. DOI: 10.3390/vaccines12121418.

Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines.

Cortes G, Ustyugova I, Farrell T, McDaniel C, Britain C, Romano C NPJ Vaccines. 2024; 9(1):228.

PMID: 39562599 PMC: 11577023. DOI: 10.1038/s41541-024-01011-x.

Influenza B Virus Vaccine Innovation through Computational Design.

Pekarek M, Weaver E Pathogens. 2024; 13(9).

PMID: 39338946 PMC: 11434669. DOI: 10.3390/pathogens13090755.

Retracted and republished from: "The current state of research on influenza antiviral drug development: drugs in clinical trial and licensed drugs".

Li Y, Huo S, Yin Z, Tian Z, Huang F, Liu P mBio. 2024; 15(5):e0017524.

PMID: 38551343 PMC: 11077966. DOI: 10.1128/mbio.00175-24.

A Universal Aptamer for Influenza A Viruses: Selection, Recognition, and Infection Inhibition.

Wang M, Hao M, Huangfu Y, Yang K, Zhang X, Zhang Y ACS Pharmacol Transl Sci. 2024; 7(1):249-258.

PMID: 38230279 PMC: 10789145. DOI: 10.1021/acsptsci.3c00258.

References

Kirkpatrick E, Qiu X, Wilson P, Bahl J, Krammer F . The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci Rep. 2018; 8(1):10432. PMC: 6041311. DOI: 10.1038/s41598-018-28706-1. View

Miller M, Gardner T, Krammer F, Aguado L, Tortorella D, Basler C . Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci Transl Med. 2013; 5(198):198ra107. PMC: 4091683. DOI: 10.1126/scitranslmed.3006637. View

KILBOURNE E . Future influenza vaccines and the use of genetic recombinants. Bull World Health Organ. 1969; 41(3):643-5. PMC: 2427719. View

Fry A, Goswami D, Nahar K, Sharmin A, Rahman M, Gubareva L . Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. 2013; 14(2):109-18. DOI: 10.1016/S1473-3099(13)70267-6. View

Sangster M, Baer J, Santiago F, Fitzgerald T, Ilyushina N, Sundararajan A . B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin Vaccine Immunol. 2013; 20(6):867-76. PMC: 3675965. DOI: 10.1128/CVI.00735-12. View

Chromikova V, Tan J, Aslam S, Rajabhathor A, Bermudez-Gonzalez M, Ayllon J . Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay. Vaccine. 2020; 38(8):1953-1961. PMC: 7117648. DOI: 10.1016/j.vaccine.2020.01.008. View

Steel J, Lowen A, Pena L, Angel M, Solorzano A, Albrecht R . Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol. 2008; 83(4):1742-53. PMC: 2643794. DOI: 10.1128/JVI.01920-08. View

Nachbagauer R, Choi A, Izikson R, Cox M, Palese P, Krammer F . Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin Stalk-Reactive Antibodies in Humans. mBio. 2016; 7(1):e01996-15. PMC: 4725014. DOI: 10.1128/mBio.01996-15. View

DiLillo D, Palese P, Wilson P, Ravetch J . Broadly neutralizing anti-influenza antibodies require Fc receptor engagement for in vivo protection. J Clin Invest. 2016; 126(2):605-10. PMC: 4731186. DOI: 10.1172/JCI84428. View

10.

Noshi T, Kitano M, Taniguchi K, Yamamoto A, Omoto S, Baba K . In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit. Antiviral Res. 2018; 160:109-117. DOI: 10.1016/j.antiviral.2018.10.008. View

11.

Pica N, Hai R, Krammer F, Wang T, Maamary J, Eggink D . Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A. 2012; 109(7):2573-8. PMC: 3289326. DOI: 10.1073/pnas.1200039109. View

12.

Hiba V, Chowers M, Levi-Vinograd I, Rubinovitch B, Leibovici L, Paul M . Benefit of early treatment with oseltamivir in hospitalized patients with documented 2009 influenza A (H1N1): retrospective cohort study. J Antimicrob Chemother. 2011; 66(5):1150-5. DOI: 10.1093/jac/dkr089. View

13.

Jefferson T, Jones M, Doshi P, Spencer E, Onakpoya I, Heneghan C . Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014; 348:g2545. PMC: 3981975. DOI: 10.1136/bmj.g2545. View

14.

He W, Chen C, Mullarkey C, Hamilton J, Wong C, Leon P . Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice. Nat Commun. 2017; 8(1):846. PMC: 5635038. DOI: 10.1038/s41467-017-00928-3. View

15.

Wu N, Wilson I . A Perspective on the Structural and Functional Constraints for Immune Evasion: Insights from Influenza Virus. J Mol Biol. 2017; 429(17):2694-2709. PMC: 5573227. DOI: 10.1016/j.jmb.2017.06.015. View

16.

Doll M, Winters N, Boikos C, Kraicer-Melamed H, Gore G, Quach C . Safety and effectiveness of neuraminidase inhibitors for influenza treatment, prophylaxis, and outbreak control: a systematic review of systematic reviews and/or meta-analyses. J Antimicrob Chemother. 2017; 72(11):2990-3007. DOI: 10.1093/jac/dkx271. View

17.

Tan G, Krammer F, Eggink D, Kongchanagul A, Moran T, Palese P . A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol. 2012; 86(11):6179-88. PMC: 3372189. DOI: 10.1128/JVI.00469-12. View

18.

Tan G, Lee P, Hoffman R, Mazel-Sanchez B, Krammer F, Leon P . Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014; 88(23):13580-92. PMC: 4248980. DOI: 10.1128/JVI.02289-14. View

19.

Stadlbauer D, Zhu X, McMahon M, Turner J, Wohlbold T, Schmitz A . Broadly protective human antibodies that target the active site of influenza virus neuraminidase. Science. 2019; 366(6464):499-504. PMC: 7105897. DOI: 10.1126/science.aay0678. View

20.

Kosik I, Angeletti D, Gibbs J, Angel M, Takeda K, Kosikova M . Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies. J Exp Med. 2019; 216(2):304-316. PMC: 6363425. DOI: 10.1084/jem.20181624. View